Evidence map›Paper›PMID 38099976›Full record

Observational studyInternational journal of clinical oncology2024

Survival outcomes of patients with stage III colorectal cancer aged ≥ 80 years who underwent curative resection: the HiSCO-04 prospective cohort study.

Tetsuya Mochizuki, Manabu Shimomura, Masahiro Nakahara, Tomohiro Adachi, Satoshi Ikeda, Yasufumi Saito, Yosuke Shimizu, Masatoshi Kochi, Yasuyo Ishizaki, Masanori Yoshimitsu and 10 more

Abstract readObservational StudyMulticenter Study
PubMed Publisher
In one paragraph

Observational study in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 2 countries.

Tetsuya MochizukiDepartment of Surgery, Onomichi General Hospital, 1-10-23 Hirahara, Onomichi, Hiroshima, Japan.
Manabu ShimomuraDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, Japan. mshimo@hiroshima-u.ac.jp.
Masahiro NakaharaDepartment of Surgery, Onomichi General Hospital, 1-10-23 Hirahara, Onomichi, Hiroshima, Japan.
Tomohiro AdachiDepartment of Surgery, Hiroshima City North Medical Center Asa Citizens Hospital, 1-2-1 Kameyamaminami, Asakita-Ku, Hiroshima, Japan.
Satoshi IkedaDepartment of Surgery, Hiroshima Prefectural Hospital, 1-5-54 Ujina-Kanda, Minami-Ku, Hiroshima, Japan.
Yasufumi SaitoDepartment of Surgery, Chugoku Rosai Hospital, 1-5-1 Tagaya, Hiro, Kure, Hiroshima, Japan.
Yosuke ShimizuDepartment of Surgery, National Hospital Organization Kure Medical Center, 3-1 Aoyama, Kure, Hiroshima, Japan.
Masatoshi KochiDepartment of Surgery, National Hospital Organization Higashihiroshima Medical Center, 513 Saijochojike, Higashihiroshima, Hiroshima, Japan.
Yasuyo IshizakiDepartment of Surgery, National Hospital Organization Hiroshima-Nishi Medical Center, 4-1-1 Kuba, Otake, Hiroshima, Japan.
Masanori YoshimitsuDepartment of Surgery, Hiroshima City Hospital, 7-33 Motomachi, Naka-Ku, Hiroshima, Japan.
Yuji TakakuraDepartment of Surgery, Chuden Hospital, 3-4-27 Otemachi, Naka-Ku, Hiroshima, Japan.
Wataru ShimizuDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, Japan.
Daisuke SumitaniDepartment of Surgery, JR Hiroshima Hospital, 3-1-36 Futabanosato, Higashi-Ku, Hiroshima, Japan.
Shinya KodamaDepartment of Surgery, Yoshida General Hospital, 3666 Yoshidachoyoshida, Akitakata, Hiroshima, Japan.
Masahiko FujimoriDepartment of Surgery, Kure City Medical Association Hospital, 15-24 Asahimachi, Kure, Hiroshima, Japan.
Mamoru OhedaDepartment of Surgery, Sera Central Hospital, 918-3 Hongo, Sera-Cho Sera-Gun, Hiroshima, Japan.
Hironori KobayashiDepartment of Surgery, Hiroshima Memorial Hospital, 1-4-3 Honkawacho, Naka-Ku, Hiroshima, Japan.
Shintaro AkabaneDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, Japan.
Takuya YanoDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, Japan.
Hideki OhdanDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, Japan.
Hiroshima University · JPHigashihiroshima Medical Center · JPHiroshima City Asa Citizens Hospital · JPHiroshima University Hospital · JPChugoku Rosai Hospital · JPHiroshima Prefectural Hospital · JPKure Medical Center · JPNishida Hospital · JPOnomichi General Hospital · JPOtemae Hospital · JPSoutheastern Retina Associates · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe efficacy of adjuvant chemotherapy in elderly patients aged ≥ 80 years with stage III colorectal cancer remains unclear. In parallel with a multicenter prospective phase II trial evaluating the efficacy of uracil-tegafur and leucovorin as adjuvant chemotherapy (HiSCO-03), we conducted a prospective observational study of these patients to assess survival outcomes, including those ineligible for chemotherapy.

methodsThis multi-institutional prospective cohort study included 17 institutions in Hiroshima, Japan. Patients aged ≥ 80 years with stage III colorectal cancer who underwent curative resection were enrolled. The primary endpoint was 3-year disease-free survival, and the secondary endpoints were 3-year overall and relapse-free survival. Propensity score matching was used to assess the effects of adjuvant chemotherapy on survival outcomes.

resultsA total of 214 patients were analyzed between 2013 and 2018, including 99 males and 115 females with a median age of 84 years (range 80-101 years). Recurrence occurred in 58 patients and secondary cancers were observed in 17. The 3-year disease-free, overall, and relapse-free survival rates were 63.3%, 76.9%, and 62.9%, respectively. Adjuvant chemotherapy was administered to 65 patients with a completion rate of 52%. In a study of 80 patients that adjusted for background factors using propensity score matching, patients who completed the planned treatment showed improved disease-free survival (3-year disease-free survival: completed, 80.0%; not received, 65.5%; and discontinued, 56.3%; p = 0.029).

conclusionsCompletion of adjuvant chemotherapy may improve the prognosis of patients with colorectal cancer aged ≥ 80 years, although the number of patients who would benefit from it is limited.

Indexed as

Colorectal NeoplasmsLevamisoleNeoplasm Recurrence, LocalAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMaleNeoplasm StagingProspective StudiesTegafurLevamisoleTegafurAdjuvant chemotherapyColorectal cancerElderly

Identifiers

PMID38099976
OpenAlexW4389781790

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.